Hennion & Walsh Asset Management, Inc. Chinook Therapeutics, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

  • $1.89 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 09, 2023
BUY
$18.66 - $38.58 $61,074 - $126,272
3,273 Added 8.86%
40,219 $1.55 Million
Q1 2023

Apr 20, 2023
BUY
$21.53 - $26.8 $227,658 - $283,383
10,574 Added 40.1%
36,946 $855,000
Q4 2022

Jan 12, 2023
BUY
$18.63 - $27.35 $491,310 - $721,274
26,372 New
26,372 $691,000

Others Institutions Holding KDNY

# of Institutions
5
Shares Held
234K
Call Options Held
0
Put Options Held
0
View Full List

About CHINOOK THERAPEUTICS, INC.

KDNY Quotes by TradingView
  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Hennion & Walsh Asset Management, Inc. Portfolio

Follow Hennion & Walsh Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email